

World Health Day 2011: combating antimicrobial resistance

Hsu L Y, Koh T H

World Health Day marks the founding of the World Health Organization (WHO). It is celebrated each year on April 7, with a theme selected each year that highlights priority public health issues for WHO that affect the international community.⁽¹⁾ The focus this year is on combating antimicrobial resistance.⁽²⁾ This is a problem virtually as old as antibiotics – Alexander Fleming had recognised that one could rapidly make microbes resistant to penicillin shortly after his famous discovery, and had sounded the first warning as early as 1945, toward the end of his Nobel prize lecture in Stockholm.⁽³⁾ However, the proliferation of effective antimicrobial agents against an ever-increasing spectrum of infectious diseases in the postwar years had drowned out such warnings, leading the then-United States Surgeon General William Stewart to say in 1969—in a much-quoted but unverified statement—that “it is time to close the book on infectious diseases and declare the war against pestilence won”.⁽⁴⁾

Via a series of converging social, political and economic factors, the situation has reversed. We live in the era of multi- and extensively drug-resistant tuberculosis (XDR-TB), artemisinin-resistant malaria, antiviral-resistant HIV, and a literal menagerie of antibiotic-resistant hospital pathogens amidst the reality of a declining antimicrobial pharmaceutical pipeline.⁽⁵⁾ For the majority of these infections, the issue is that of cost and access; there are effective drugs, but they are either unavailable or unaffordable in areas where they are needed the most. For the rare few nosocomial pandrug-resistant Gram-negative infections, no effective antibiotics are projected over the next 5–10 year horizon.

Singapore is fortunate in that the prevalence of primary HIV drug resistance,⁽⁶⁾ XDR-TB⁽⁷⁾ and autochthonous malaria⁽⁸⁾ remains negligible. However, nosocomial bacterial drug resistance rates are high in public hospitals.⁽⁹⁾ The situation in the large private sector is unknown, as no data is publicly available. As the medical tourism industry grows, the import (and export) of drug-resistant bacteria from (and to) overseas hospitals and communities will continue to increase. This is highlighted again in the case reported by Chan et al in this issue of the *Singapore Medical Journal*.⁽¹⁰⁾ Bacteraemia due to New Delhi metallo-β-lactamase-1 (NDM-1)-producing *Escherichia coli* occurred in a medical tourist from Bangladesh following




Fig. 1 Percentage susceptibility of *Neisseria gonorrhoeae* to various antibiotics. Based on data from the WHO Gonococcal Antimicrobial Surveillance Programme and the Singapore General Hospital microbiology laboratory.⁽¹¹⁾

chemotherapy for acute lymphoblastic leukaemia. The index patient died, but fortunately, the bacterium did not spread to other patients.⁽¹⁰⁾

Less work, however, has been done at the community level, but there are suggestions that antimicrobial resistance rates are increasing here as well, best exemplified by the *Neisseria gonorrhoeae* susceptibility results submitted by the Department of Pathology, Singapore General Hospital to the WHO Gonococcal Antimicrobial Surveillance Programme since 1992 (Fig. 1). Fluoroquinolone resistance increased from < 10% pre-1999 to > 70% by 2007, where it has remained since.⁽¹¹⁾

The solutions are clear, but implementation is difficult without political will that is supported by concerted action on the ground. Being a small country with no real agricultural industry, Singapore can influence neither the global development of antimicrobial agents nor the use of antibiotics as growth promoters in animal husbandry. Nonetheless, effective action remains possible, as previously suggested.⁽¹²⁾ The recently convened National Antimicrobial Taskforce has submitted recommendations to the Ministry of Health for controlling bacterial drug resistance in public hospitals. This is a good start, if accepted, but the current narrow focus does not include all segments of the healthcare industry. Public campaigns targeting both the general public and physicians may be useful for improving the use of antibiotics in the outpatient and primary care setting.⁽¹³⁾ Finally, increased funding for

Department of Medicine, National University Health System, 1E Kent Ridge Road, NUHS Tower Block Level 10, Singapore 119228

Hsu LY, MPH
Assistant Professor

Department of Pathology, Singapore General Hospital, Outram Road, Singapore 169608

Koh TH, D(ABMM)
Senior Consultant and Associate Professor

Correspondence to:
Dr Hsu Li Yang
Tel: (65) 6779 5555
Fax: (65) 6779 5678
Email: liyang_hsu@yahoo.com

research into the design of novel antimicrobial agents and/or their testing may align the aims of the local biomedical research industry toward addressing this major public health threat.

REFERENCES

1. World Health Organization. World Health Day [online]. Available at: www.who.int/world-health-day/previous/en/. Accessed March 31, 2011.
2. World Health Organization. World Health Day – 7 April 2011 [online]. Available at: www.who.int/world-health-day/2011/en/index.html Accessed March 31, 2011.
3. Fleming A. Nobel lecture: Penicillin [online]. Available at: nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf Accessed March 31, 2011.
4. Spellberg B. Dr William H Stewart: mistaken or maligned? Clin Infect Dis 2008; 47:294.
5. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
6. Lee CC, Sun YJ, Barkham T, Leo YS. Primary drug resistance and transmission analysis of HIV-1 in acute and recent drug-naïve seroconverters in Singapore. HIV Med 2009; 10:370-7.
7. Cutter J, Wang YT. Tuberculosis – an under-appreciated disease. Ann Acad Med Singapore 2010; 39:261-2.
8. Ng LC, Lee KS, Tan CH, et al. Entomologic and molecular investigation into Plasmodium vivax transmission in Singapore, 2009. Malar J 2010; 9:305.
9. Hsu LY, Tan TY, Tam VH, et al. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother 2010; 54:1173-8.
10. Chan HLE, Poon LM, Chan SG, Teo JWP. The perils of medical tourism: NDM-1-positive Escherichia coli causing febrile neutropenia in a medical tourist. Singapore Med J 2011; 4:299-302.
11. World Health Organization. Gonococcal Antimicrobial Surveillance Programme [online]. Available at: www.wpro.who.int/sites/hsi/sti/gasp.htm?more=yes Accessed March 31, 2011.
12. Hsu LY, Kwa AL, Lye DC, et al. Reducing antimicrobial resistance through appropriate antibiotic usage in Singapore. Singapore Med J 2008; 49:749-55.
13. Huttner B, Goossens H, Verheij T, Harbarth S; CHAMP consortium. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet Infect Dis 2010; 10:17-31.



inactivates 99.9% of pandemic influenza H1N1*

TRIPLE PROTECTION

- ① Cleans: Neutralizes contaminated droplets*
- ② Inactivates: Destroys viruses*
- ③ Filters: Enhanced microbial protection*

Reduces risks of cross-contamination of hands and surfaces**
Designed for all-day comfort
Excellent breathability

Registered Class A Medical Device under Singapore Health Products Act
CE certified: EN14683, Type IIR surgical face mask
Exceeds ASTM F2100-07 high barrier surgical face mask standards

*BioMask™ inactivates 99.9% of the following viruses after five minutes of contact with the surface of the face mask based on laboratory tests only

Subtype	Isolate	Neutral Control Mask	BioMask®
INFLUENZA A >99.9% after 5 minutes			
H1N1	A/California/07/09 A/Fujian/07 A/Wisconsin/10/98 A/New Jersey/8/76 A/PR/8/34 A/Swine/1976/31	29.2 69.4 58.3 48.7 49.9 91.7	99.99 99.99 99.99 99.99 99.99 99.99
H2N2	A/2/Japan/205/57 A/Paris/07/07 A/Wisconsin/6/2005 A/Hong Kong/8/68 A/Victoria/3/75	48.7 48.3 43.8 68.4	99.99 99.99 99.99 99.99
H3N2	A/2/Spain/305/57 A/Paris/07/07 A/Wisconsin/6/2005 A/Hong Kong/8/68 A/Victoria/3/75	66.7 48.7 48.3 43.8 68.4	99.99 99.99 99.99 99.99 99.99
H5N1	N/BRG-14	73.7	99.99
H5N2	A/Duck/PA/102/18/84	NR	99.99
H9N2	Turkey/Wisconsin/66	NR	99.99
H3N8	A/Equine/2/Miami/63	60.2	99.99
INFLUENZA B >99.9% after 5 minutes			
B	B/Brisbane/60/2008 B/Florida/4/2008 B/Leeds/40	68.4 25.9 53.2	99.99 99.99 99.99

NR = No Reduction of Challenge Virus Observed

The following pathogens have also been shown to be inactivated on contact with the inner layer of the relevant mask:

Pathogen	Neutral Control Mask	BioMask®
Coronavirus (SARS) [†]	after 1 minute	98.22 \geq 99.99
Rhinovirus	after 1 minute	70.49 \geq 96.61
MRSA	after 30 minutes	84.00 \geq 99.90
Measles	after 1 minute	99.68 \geq 99.99

All of the above tests were designed based on AATCC Test Method 100-2004 Antimicrobial Finishes on Textile Materials Assessment of, with customization for virus testing. Results presented show reduction of the challenge virus inoculum. These laboratory tests were not clinically tested on humans.

How it works: The BioMask™ facemask is coated with a hydrophilic (water-loving) coating that draws aerosol droplets away from the surface of the mask into the inner layers where pathogens are inactivated by the low pH and the divalent metal ions, copper and zinc.

^{*} Provides 350x greater barrier protection against live influenza virus compared to a standard ASTM F2100-07 high barrier mask, based on laboratory tests. Inactivates >99.99% of influenza virus on 5 minutes contact.
[†] Using Human Coronavirus (229E) as a surrogate for the SARS-causing coronavirus.

WARNING: This surgical face mask cannot stop the transmission of all germs in the air and does not eliminate the risk of disease or illness. Practice good hygiene. Sanitise hands frequently and refrain from touching nose, mouth or eyes. Do not clean or sterilise for re-use.

innovation by:
filligent
Pragmatic • Scientific • Patented
© Filligent Limited. All rights reserved.
Filligent (HK) Limited
7th Floor, 69 Jervois Street,
Sheung Wan, Hong Kong

Importer/Distributor for Singapore:
WEIS
WEIS Traders Ltd

WEIS's Sub-distributor (Medical Industry):
LOZON
LOZON (S) PTE. LIMITED

LOZON (S) LTD
51 Ubi Ave 1 #03-29
Paya Ubi Industrial Park
Singapore 408933

Tel: +65 6299 9123
Fax: +65 6286 7293
Email: sales@weistraders.com

Tel: +65 6299 1617
Fax: +65 6299 1617
http://www.lozon.com.sg